Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

CollPlant Biotechnologies Ltd

  • Public · NASDAQ: CLGN
  • 39 employees
$5.4MMarket cap
$2.4MRevenue · FY2025
-$11.5MNet income
39Employees
CLGNNASDAQ
2021IPO

About CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$2.4M
Net income
-$11.5M
Total assets
$10.8M
Market cap
$5.4M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: CLGN

15-minute delayed · data by Polygon.io

Market cap
$5.4M
Open
Day range
Prev close
Volume
IPO date
Jun 4, 2021

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review CollPlant Biotechnologies Ltd.

Write a review
Explore

Similar companies

Browse all →